

2026 Current Fiscal Year Report: Cellular Tissue and Gene Therapies Advisory Committee

Report Run Date: 05/05/2026 03:08:13 PM

1. Department or Agency

Department of Health and Human
Services

2. Fiscal Year

2026

3. Committee or Subcommittee

Cellular Tissue and Gene Therapies
Advisory Committee

3b. GSA Committee No.

127

4. Is this New During Fiscal Year? 5. Current Charter 6. Expected Renewal Date 7. Expected Term Date

No 10/28/2024 10/28/2026

8a. Was Terminated During Fiscal Year? 8b. Specific Termination Authority 8c. Actual Term Date

No

9. Agency Recommendation for Next Fiscal Year 10a. Legislation Req to Terminate? 10b. Legislation Pending?

Continue Not Applicable Not Applicable

11. Establishment Authority Authorized by Law

12. Specific Establishment Authority 13. Effective Date 14. Committee Type 14c. Presidential?

21 U.S.C. 394 11/28/1990 Continuing No

15. Description of Committee Scientific Technical Program Advisory Board

16a. Total Number of Reports

No Reports for
this Fiscal Year

17a. Open 17b. Closed 17c. Partially Closed 17d. Total

Meetings and Dates

No Meetings

	Current	Next
	FY	FY
18a(1). Personnel Pmts to Non-Federal Members	\$0.00	\$0.00
18a(2). Personnel Pmts to Federal Members	\$0.00	\$0.00
18a(3). Personnel Pmts to Federal Staff	\$0.00	\$0.00
18a(4). Personnel Pmts to Non-Member Consultants	\$0.00	\$0.00
18b(1). Travel and Per Diem to Non-Federal Members	\$0.00	\$0.00
18b(2). Travel and Per Diem to Federal Members	\$0.00	\$0.00
18b(3). Travel and Per Diem to Federal Staff	\$0.00	\$0.00
18b(4). Travel and Per Diem to Non-member Consultants	\$0.00	\$0.00
18c. Administrative Costs (FRNs, contractor support, In-person/hybrid/virtual meetings)	\$0.00	\$0.00
18d. Other (all other funds not captured by any other cost category)	\$0.00	\$0.00
18e. Total Costs	\$0.00	\$0.00
19. Federal Staff Support Years (FTE)	0.00	0.00

20a. How does the Committee accomplish its purpose?

The Committee reviews and evaluates available data relating to the safety, effectiveness, and appropriate use of human cells, human tissues, gene therapies, and xenotransplantation products which are intended for transplantation, implantation, infusion, and transfer in the prevention and treatment of a broad spectrum of

human diseases and in the reconstruction, repair, or replacement of tissues for various conditions. On November 21, 2024, the Committee met in open session to discuss and make recommendations on supplemental biologics license application 125586/546 from AstraZeneca AB, submitted to confirm the clinical benefit of Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo), for patients treated with rivaroxaban or apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding. The FDA considered the recommendations of CTGTAC in its review of sBLA 125586/546. Approval for Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo) for the proposed indication was not granted.

20b. How does the Committee balance its membership?

Members have clinical or preclinical and product experience in the fields of cellular therapies, tissue transplantation, gene therapies, and xenotransplantation. These may include biostatistics, bioethics, hematology/oncology, human tissues and transplantation, reproductive medicine, general medicine, and various medical specialties including surgery and oncology, immunology, virology, molecular biology, cell biology, developmental biology, tumor biology, biochemistry, rDNA technology, nuclear medicine, gene therapy, infectious diseases, and cellular kinetics. One member is technically qualified and identified with consumer interests and one non-voting member represents the point of view of industry.

20c. How frequent and relevant are the Committee Meetings?

The committee held one (1) advisory committee meeting on November 21, 2024, and one site visit on December 5-6/2024. It is anticipated the committee may have two (2) advisory committee meetings FY 2026.

20d. Why can't the advice or information this committee provides be obtained elsewhere?

Members of the Committee are drawn from academia, research, and/or clinical practice. Their advice and input lends credibility to regulatory decisions. The alternate means of obtaining this advice would involve the recruitment of large numbers of scientists on a full-time basis at maximum rates of compensation.

20e. Why is it necessary to close and/or partially closed committee meetings?

The committee held no closed meetings in FY 2025.

21. Remarks

The Agency considered the recommendations of the Committee from the November 21, 2023 CTGTAC meeting. Approval was not granted for supplemental biologics license application 125586/546 from AstraZeneca AB, submitted to confirm the clinical benefit of Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo), for patients treated with rivaroxaban or apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding. The Committee agreed that while treatment with Andexxa appears to lead to achievement of hemostatic efficacy at 12 hours, the efficacy data provided did not clearly show a clinically meaningful benefit. The Committee found it challenging to assess the risks of Andexxa (e.g., increased rate of thrombotic events in

Andexxa-treated patients) in the context of its current indication, given that ANNEXA-I only evaluated Andexxa in patients with life-threatening intracerebral hemorrhage after receiving oral anticoagulants (apixaban or rivaroxaban). The FDA issued a Complete Response Letter (CRL) denying granting full approval (i.e., conversion from accelerated to full approval) for Andexxa's supplemental biologics license application.

Designated Federal Officer

Cicely Reese Designated Federal Officer

Committee Members	Start	End	Occupation	Member Designation
Ahsan, Tabassum	05/17/2021	03/31/2026	Vice President, Cell and Gene Therapy Operations, City of Hope, Duarte, CA	Special Government Employee (SGE) Member
Breuer, Christopher	06/07/2018	03/31/2026	Director of Tissue Engineering Program and Surgical Research Director, Center for Regenerative Medicine, Director, Center for Regenerative Medicine, Nationwide Children's Hospital, Columbus, OH	Special Government Employee (SGE) Member
Eggimann, Anne-Virginie	07/18/2024	03/31/2028	Industry Representative - Chief Regulatory Officer, Tessera Therapeutics, Inc., Somerville, MA	Representative Member
London, Wendy	04/01/2023	03/31/2027	Associate Professor of Pediatrics, Boston Children's Hospital/Dana-Farber Cancer Institute, Harvard Medical School	Special Government Employee (SGE) Member

Lund, Troy	08/30/2024	03/31/2028	Associate Professor, Associate Director Metabolic Program, Pediatric Blood and Marrow Transplant Fellowship Director, Leukodystrophy Center of Excellence, Div. of Pediatric Blood and Marrow Transplantation and Cellular Therapy, Univ. of MN Medical Center	Special Government Employee (SGE) Member
Morrison, Sean	06/07/2018	03/31/2026	Director, Children's Medical Research Institute, University of Texas Southwestern Medical Center, Dallas, TX	Special Government Employee (SGE) Member
Ott, Melanie	04/01/2022	03/31/2026	Director, Senior Investigator, Gladstone Institute of Virology, Senior Vice President, Gladstone Institutes, University of California, San Francisco, San Francisco, CA	Special Government Employee (SGE) Member
Shah, Nirali	02/04/2022	03/31/2026	Head, Hematologic Malignancies Section, Pediatric Oncology Branch, Lasker Clinical Research Scholar, National Cancer Institute, National Institutes of Health, Bethesda, MD	Regular Government Employee (RGE) Member
Snyder, Evan	08/30/2024	03/31/2028	Director, Center for Stem Cells and Regenerative Medicine, Professor, Human Genetics Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA	Special Government Employee (SGE) Member

diseases and in the reconstruction, repair, or replacement of tissues for various conditions. The Committee also considers the quality and relevance of FDA's research program, which provides scientific support for the regulation of these products. The Committee supports FDA's mission by using science-based risk management in all its activities. The Committee recommendations provide the most health promotion and protection at the least cost to the public. This Committee assists the Agency in ensuring timely, high-quality, cost-effective processes for review of new technologies/pre-market submissions, effective communication and working relationships with stakeholders to enhance U.S. and global health outcomes, accurate analysis of risks associated with medical products, facilitation of the development and availability of medical countermeasures to limit the effects of a terrorist attack on the civilian and military populations, and protection of the safety and security of biologics (gene therapy, human tissues, and cellular therapies) – all key components of FDA's strategic plan objectives.

What are the most significant program outcomes associated with this committee?

	Checked if Applies	
Improvements to health or safety	<input checked="" type="checkbox"/>	✓
Trust in government	<input checked="" type="checkbox"/>	✓
Major policy changes	<input checked="" type="checkbox"/>	✓
Advance in scientific research	<input checked="" type="checkbox"/>	✓
Effective grant making	<input type="checkbox"/>	
Improved service delivery	<input type="checkbox"/>	
Increased customer satisfaction	<input checked="" type="checkbox"/>	✓
Implementation of laws or regulatory requirements	<input checked="" type="checkbox"/>	✓
Other	<input type="checkbox"/>	

Outcome Comments

Not Applicable

What are the cost savings associated with this committee?

Checked if Applies

- None
- Unable to Determine
- Under \$100,000
- \$100,000 - \$500,000
- \$500,001 - \$1,000,000
- \$1,000,001 - \$5,000,000
- \$5,000,001 - \$10,000,000
- Over \$10,000,000
- Cost Savings Other

Cost Savings Comments

The utilization of the Cellular, Tissue, and Gene Therapies Advisory Committee enables the Agency to obtain required and frequently scarce professional services from medical and scientific experts not otherwise available to the Agency, and to obtain the services of these experts only on an as-needed basis rather than a full-time basis. The services of the Committee resulted in advice for the improvement of the public health, for which it is difficult to assign a financial value.

What is the approximate Number of recommendations produced by this committee for the life of the committee?

101

Number of Recommendations Comments

The Committee made 101 recommendations from FY 2003 through FY 2025.

What is the approximate Percentage of these recommendations that have been or will be Fully implemented by the agency?

84%

% of Recommendations Fully Implemented Comments

The function of an advisory committee is purely advisory in nature. Although the FDA most often accepts the recommendations from its committees, the advice is purely advisory in nature, and therefore, the Agency has the option of not implementing the advice.

What is the approximate Percentage of these recommendations that have been or will be Partially implemented by the agency?

10%

% of Recommendations Partially Implemented Comments

The function of an advisory committee is purely advisory in nature. Although the FDA most often accepts the recommendations from its committees, the advice is purely advisory in nature, and therefore, the Agency has the option of not implementing the advice.

Does the agency provide the committee with feedback regarding actions taken to implement recommendations or advice offered?

Yes No Not Applicable

Agency Feedback Comments

When appropriate, information is made available to the public. Actions related to guidance documents or other general matters issues are available publicly when implemented.

What other actions has the agency taken as a result of the committee's advice or recommendation?

Checked if Applies

Reorganized Priorities	<input checked="" type="checkbox"/>
Reallocated resources	<input type="checkbox"/>
Issued new regulation	<input checked="" type="checkbox"/>
Proposed legislation	<input type="checkbox"/>
Approved grants or other payments	<input type="checkbox"/>
Other	<input checked="" type="checkbox"/>

Action Comments

FDA approves or chooses not to approve an investigational medical product or other regulatory decision-making.

Is the Committee engaged in the review of applications for grants?

No

Grant Review Comments

NA

How is access provided to the information for the Committee's documentation?

Checked if Applies

Contact DFO	<input checked="" type="checkbox"/>
Online Agency Web Site	<input checked="" type="checkbox"/>

Online Committee Web Site



Online GSA FACA Web Site



Publications



Other



Access Comments

N/A